Investigating the role of CD9 gene regulation in childhood leukemia relapses

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project focuses on B-acute lymphoblastic leukaemia (B-ALL), the most common cancer in children, particularly examining the role of the CD9 gene in patient relapses. The study involves collecting bone and blood samples from newly diagnosed patients at three critical points during their treatment. Researchers aim to understand how non-coding RNAs regulate CD9 expression, which may serve as a marker for potential relapses. If successful, this could lead to new diagnostic and therapeutic strategies for managing B-ALL.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Under 18 years
* With established diagnosis of B-ALL
* Initial diagnosis made in the investigating centre
* Having received oral and written information about the protocol, or oral only if the patient is unable to read.
* Having signed a consent form if the patient is capable of giving informed written consent.
* Whose legal guardians have received oral and written information about the protocol, and have signed a free, informed and written consent.
* Beneficiary of a social security scheme

Exclusion Criteria:

* Isolated extramedullary involvement at inclusion
* Patient of childbearing age without effective contraception.
* Adult subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty.

Where it's running

• CHU Angers
  Angers, France Recruiting
• CHU Brest
  Brest, France Recruiting
• CHU Rennes
  Rennes, France Recruiting

Study contacts

• Study coordinator: Elie COUSIN, Md
• Email: elie.cousin@univ-rennes.fr
• Phone: 299284321

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Assessing adrenal function in children with leukemia after glucocorticoid treatment

  This study is trying to see how glucocorticoid treatment affects the adrenal function in children with leukemia to better understand and manage any potential hormone problems they might have after treatment.

  Recruiting at 2 sites University Children's Hospital Basel · Aarau and 1 other locations · NCT06861530

• Ph+ ALL in Chinese Children: Diagnosis, Treatment, and Survival

  This study tests how children in China with Philadelphia chromosome–positive ALL are diagnosed, treated, and how long they survive in real-world practice.

  Recruiting The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07813208

• Finding the right dose of MB-CART2219.1 CAR‑T (targets CD19 and CD22) for relapsed B‑cell cancers

  This trial will test MB‑CART2219.1, a CAR‑T cell therapy that targets CD19 and CD22, in adults and children with relapsed or refractory B‑cell cancers to find a safe dose.

  Recruiting Phase 1 University Hospital Tuebingen · Tübingen, Baden-Wurttemberg and 1 other locations · NCT07108868

• Impact of massage therapy on sleep in young cancer patients

  This study is testing whether personalized massage therapy can help young cancer patients in the hospital sleep better and feel less tired, anxious, and in pain during their treatment.

  Recruiting Children's Hospital of Philadelphia · Washington D.C., District of Columbia and 1 other locations · NCT06892158

• CAR-T cell therapy for children with relapsed leukemia or lymphoma

  This study is testing a new CAR-T cell therapy to see if it can help children with relapsed leukemia or lymphoma feel better and improve their chances of recovery.

  Recruiting Hong Kong Children's Hospital · Hong Kong · NCT06866873

• Using virtual reality to ease lumbar punctures in children with leukemia

  This study is testing whether using virtual reality can help kids with leukemia feel less pain and anxiety during lumbar punctures, so they might not need general anesthesia.

  Recruiting Children's National Research Institute · Washington D.C., District of Columbia · NCT06722638

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.